Internal Medicine, Hematology & Oncology · Royal Oak, MI
NPI
1528068020
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
3577 W 13 Mile Rd, Suite 204
Royal Oak, MI, 48073
Phone (248) 551-2446
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.6M
155,043 services
Medicare patients, 2024
671
Average age 75
Drug cost, 2024
$4.9M
1,705 prescriptions
Company payments, 2025
$7,197
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Samer Ballouz was code J1439 (injection, ferric carboxymaltose, 1 mg), 39,750 times for 29 patients. In total Samer Ballouz billed 155,043 services in 124 codes, and Medicare paid $2.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-03-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 39,750 | 29 | $0.87 | $35K |
| J0897 Injection, denosumab, 1 mg | Office | 13,800 | 33 | $20.54 | $284K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 5,000 | 13 | $44.27 | $221K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 4,500 | 14 | $0.11 | $511 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 4,224 | 13 | $20.58 | $87K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 4,060 | 14 | $2.37 | $9,615 |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2,850 | 12 | $31.61 | $90K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,420 | 33 | $6.35 | $15K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,759 | 50 | $0.09 | $160 |
| 85025 Blood Count | Office | 1,192 | 402 | $7.48 | $8,913 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 1,060 | 12 | $5.00 | $5,300 |
| 80047 Clinical Chemistry | Office | 993 | 351 | $13.26 | $13K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 770 | 34 | $0.76 | $589 |
| 99214 Office E&M - Established | Office | 612 | 206 | $97.67 | $60K |
| 99232 Hospital E&M - Subsequent | Facility | 551 | 156 | $61.72 | $34K |
By year: 2022 $2.9M for 175,518 services; 2023 $2.2M for 170,896 services; 2024 $2.6M for 155,043 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,192 | 402 | $7.48 | $8,913 |
| 80047 Clinical Chemistry | 993 | 351 | $13.26 | $13K |
Medicare prescription drug claims, 2024
In 2024, the drug Samer Ballouz prescribed most often to Medicare patients was Letrozole, with 146 prescriptions and refills. In total Samer Ballouz wrote 1,705 Medicare prescriptions that cost $4.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 146 | 212 | 26 | $2,324 |
| Hydroxyurea Generic | 127 | 184 | 24 | $2,846 |
| Anastrozole Generic | 118 | 262 | 30 | $2,772 |
| Prednisone Generic | 102 | 104 | 39 | $735 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 87 | 87 | 33 | $1,757 |
| Xtandi Enzalutamide | 87 | 87 | 13 | $1.1M |
| Eliquis Apixaban | 77 | 83 | 20 | $47K |
| Ondansetron Hcl Generic | 52 | 53 | 33 | $502 |
| Oxycodone Hcl Generic | 49 | 49 | 16 | $1,121 |
| Ibrance Palbociclib | 48 | 48 | Under 11 | $763K |
| Xarelto Rivaroxaban | 45 | 63 | Under 11 | $34K |
| Calquence Acalabrutinib Maleate | 39 | 39 | Under 11 | $572K |
| Temazepam Generic | 36 | 36 | Under 11 | $137 |
| Imatinib Mesylate Generic | 34 | 34 | Under 11 | $18K |
| Alprazolam Generic | 32 | 32 | 12 | $205 |
Brand drugs: 429 claims; generic drugs: 1,276 claims; opioid claims: 188.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Samer Ballouz $7,197 ($7,197 in general payments such as food, travel and fees) from 6 companies. The largest payer was Avyxa Pharma, LLC with $3,664.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.